Bristol-Myers Squibb Company (BMY) Shares Bought by Commerce Bank
Commerce Bank raised its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 320,054 shares of the biopharmaceutical company’s stock after buying an additional 777 shares during the period. Commerce Bank’s holdings in Bristol-Myers Squibb were worth $17,405,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Swiss National Bank raised its position in shares of Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares during the period. Karp Capital Management Corp acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth approximately $38,890,000. Canada Pension Plan Investment Board raised its position in shares of Bristol-Myers Squibb by 23.8% in the first quarter. Canada Pension Plan Investment Board now owns 3,362,609 shares of the biopharmaceutical company’s stock worth $182,859,000 after buying an additional 646,000 shares during the period. Mizuho Securities USA Inc. acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth approximately $20,383,000. Finally, Polaris Greystone Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth approximately $15,109,000. 69.68% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Company (BMY) traded up 0.34% during trading on Friday, hitting $58.37. The company had a trading volume of 4,070,765 shares. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $60.45. The firm has a 50-day moving average of $56.20 and a 200 day moving average of $55.23. The company has a market capitalization of $95.72 billion, a price-to-earnings ratio of 21.32 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same period last year, the company posted $0.69 EPS. The business’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.67%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
A number of research analysts recently issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating and set a $66.00 target price (up from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday. Vetr lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price on the stock. in a report on Tuesday, August 22nd. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Wednesday, August 16th. Cowen and Company set a $65.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, August 14th. Finally, BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $62.31.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.